Although agents available for controlling disease in mild ulcerative colitis (UC) are largely effective and well tolerated, many unmet needs exist in treating moderate to severe disease, and sizeable opportunity remains for therapies that target this patient population. Novel agents that can more effectively induce remission, achieve mucosal healing, and/or reduce corticosteroid use relative to the leading TNF-alpha inhibitors are areas of important need. With another cell adhesion molecule (CAM) inhibitor, an oral Janus-activated kinase (Jak) inhibitor, and an oral sphingosine-1-phosphate receptor (S1P-R) inhibitor in late-stage development for moderate to severe UC, the competition in the moderate to severe UC space is intensifying; novel agents will need to differentiate themselves in efficacy or safety in order to capture appreciable market share.

Related Reports

Ulcerative Colitis | Current Treatment | Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis (US) - Pediatric

MARKET OUTLOOK Conventional therapies (5-ASAs, corticosteroids) are typically used to treat mild to moderate pediatric ulcerative co...

View Details

Ulcerative Colitis | Landscape & Forecast | Disease Landscape & Forecast

The ulcerative colitis (UC) market is expected to grow steadily over the next decade. The entry of first-in-UC oral...

View Details

Ulcerative Colitis | Epidemiology | Extrapolated Worldwide Coverage

DRG’s Extrapolated Worldwide Coverage is the first and only evidence-based data set of epidemiological forecasts for key ulcerative colitis pat...

View Details

Ulcerative Colitis | Current Treatment | Detailed, Expanded Analysis (EU5)

Multiple well-established therapies are currently available to treat ulcerative colitis (UC) in Europe. TNF-&alp...

View Details